Barostim implant rollout at Staten Island University Hospital advances device availability, CVRx initiative

Barostim implant rollout at Staten Island University Hospital advances device availability, CVRx initiative
CVRx, Staten Island device milestone

CVRx has announced a partnership with Staten Island University Hospital to deliver the hospital's first Barostim implant. This collaboration involved Dr. Kenneth Dulnuan, Dr. Jonathan Schor, Stacey Quinones, MSN, FNP-C, Gresa Bajraktarevic, MS, PA-C, and the clinical team.

The Barostim device introduces a novel therapy option now available to patients, representing a step forward in innovative treatment for challenging cardiovascular conditions. The move underscores growing adoption of device-based therapies in hospital settings.

CVRx previously announced Barostim therapy as an approach targeting the root mechanisms of heart failure. Company executive Philip Adamson discussed his perspective on the evolution of heart failure treatments in a recent medical podcast appearance. These initiatives reflect ongoing developments in CVRx’s heart failure care portfolio.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.